

NEWS RELEASE



December 23, 2024

News Regarding the Verdict of the Trial in the U.S. Lawsuit with Sarepta

Kyoto, Japan, December 23, 2024 - Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”; headquarters: Kyoto, Japan; President: Toru Nakai) announces that following a trial held in the U.S. District Court for the District of Delaware (Wilmington, Delaware) from December 16 to 20, 2024, a jury verdict found that a patent obtained by Sarepta Therapeutics, Inc. (“Sarepta”) from the University of Western Australia (“UWA”) (the “UWA Patent”) is valid and awarded Sarepta \$115.2 million in damages based on Nippon Shinyaku’s sale of Viltepso, a treatment for Duchenne muscular dystrophy. Nippon Shinyaku also announces that the jury verdict found that Nippon Shinyaku’s patents are invalid.

On July 14, 2021, Nippon Shinyaku filed a lawsuit against Sarepta in the U.S. District Court for the District of Delaware to defend its intellectual property. Sarepta subsequently filed counterclaims for infringement of its intellectual property.

Nippon Shinyaku does not agree with the jury verdict and will consider all options, including post-jury motions and appeals, with respect to the jury verdict.

It should be noted that this jury verdict will have no bearing on the sales of Viltepso or the development of our other exon-skipping drug candidates.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

e_mail_kouhou@po.nippon-shinyaku.co.jp